CSF2 and ovarian cancer: In a phase II study of 27 women with recurrent platinum-resistant ovarian cancer presented at SGO 2018, the combination of TPIV200 with GM-CSF and durvalumab was safe and tolerable and resulted in durable disease control in a number of patients [44].